JWA
MRTX

JFS Wealth Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

JFS Wealth Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 2006
2021
Q4 		$0 Sell
1
-17
-94% -$2.64K ﹤0.01% 1928
2021
Q3 		$3K Buy
+18
New +$2.9K ﹤0.01% 762

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JFS Wealth Advisors's MRTX Position: Q1 2022 in Review

JFS Wealth Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 1 share.

JFS Wealth Advisors first reported a position in MRTX in Q3 2021 and held it in 2 quarters. The position peaked at $3K in Q3 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • JFS Wealth Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • JFS Wealth Advisors sold 1 Mirati Therapeutics, Inc. Common Stock share in Q1 2022.
  • JFS Wealth Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • JFS Wealth Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $3K in Q3 2021.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on JFS Wealth Advisors's 13F filing for Q1 2022, filed 2 May 2022.